[Interstitial pneumonitis following high-dose MCNU].
We describe a 11-year-old boy with NHL, who developed interstitial pneumonitis following high-dose MCNU with autologous peripheral stem cell transfusion. Non-productive cough, malaise and progressive dyspnea on exertion were noticed 7 weeks after high-dose MCNU (600 mg/kg) treatment, and chest X-ray revealed a bibasilar reticular pattern. Arterial blood was hypoxemic and pulmonary function showed the development of a restrictive ventilatory effect and a reduced diffusing capacity for carbon monoxide (DLCO). Clinical Symptoms were resolved after 3 courses of m-PSL pulse therapy and 6 months prednisolone, but an isolated reduction in DLCO has been present. This case suggests that pulmonary toxicity is a dose limiting factor for MCNU treatment.
Shimokawa
T
T
Dept. of Pediatrics, Shikoku Cancer Center.
Koyama
T
T
Takaue
Y
Y
Watanabe
T
T
Kawano
Y
Y
Ninomiya
T
T
Kuroda
Y
Y
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000628:therapy; D008297:Male; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D011653:Pulmonary Diffusing Capacity; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000503:physiopathology
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C020766:ranimustine